



Received on 11 July, 2011; received in revised form 15 October, 2011; accepted 08 December, 2011

SOLUBILITY ENHANCEMENT OF POORLY WATER SOLUBLE DRUGS BY SOLID DISPERSION

A. K. Chaturvedi¹ and Amita Verma*²

Kharvel Subharti College of Pharmacy, SVSU¹, Meerut, Uttar Pradesh, India

Department of Pharmaceutical Chemistry, Christian school of Pharmacy, Sam Higginbottom Institute of Agriculture, Technology and Sciences², Allahabad, Uttar Pradesh, India

Keywords:

Solid Dispersions,
Solubility Enhancement,
Fusion,
Solvent Evaporation,
Electro Static Spinning

Correspondence to Author:

Amita Verma

Department of Pharmaceutical Chemistry,
Christian school of Pharmacy, Sam
Higginbottom Institute of Agriculture,
Technology and Sciences, Allahabad, Uttar
Pradesh, India

ABSTRACT

Solid dispersions have been employed to enhance the dissolution rates of poorly water-soluble drugs. Many approaches have been investigated for the preparation of solid dispersions. This paper reports the various solubility enhancement strategies in solid dispersion. The approaches described are fusion (melting), solvent evaporation, lyophilization (freeze drying), melt agglomeration process, extruding method, spray drying technology, use of surfactant, electro static spinning method and super critical fluid technology. This paper also highlights the potential applications and limitations of these approaches in solid dispersions.

INTRODUCTION: Drug substances are seldom administered alone, but rather as part of a formulation in combination with one or more non-medicinal agents that serve varied and specialized pharmaceutical function. The proper design and formulation of a dosage form requires consideration of the physical, chemical and biological characteristics of all the drug substances and pharmaceutical ingredients to be used in fabricating the product.

An important physical-chemical property of a drug substance is solubility, especially aqueous system solubility. A drug must possess some aqueous solubility for therapeutic efficacy. For a drug to enter the systemic circulation to exert a therapeutic effect it must be in solution¹. Recent technologies innovation of combinatorial chemistry and high throughput screening can effectively discover the seeds of new drugs, which present good pharmacological activities. However 35-40 % of these new drugs discovered by

those technologies suffer from poor aqueous solubility²⁻³.

The solubility/dissolution behavior of a drug is key determinant to its oral bioavailability, the latest frequency being the rate-limiting step to absorption of drugs from the gastrointestinal tract⁴⁻⁶. Consequently poor solubility results in low bioavailability, increase in the dosage, large inters and intra-subject variation and large variations in blood drug concentrations under fed versus fasted conditions.

Improvement of oral bioavailability of poorly water-soluble drugs remains one of the most challenging aspects of drug development. The techniques/approaches that have commonly been used to overcome drawbacks associated with poorly water-soluble drugs, in general includes micronization, salt formation, use of surfactant and use of pro-drug⁷⁻⁸. However, all these techniques have potential limitations.

Micronization has several disadvantages, the main one being the limited opportunity to control important characters of the final particle such as size, shape, morphology, surface properties and electrostatic charges. In addition micronization is a high-energy process, which causes disruptions in the drug's crystal lattice, resulting in the presence of disordered or amorphous regions in the final product. The amorphous regions are thermodynamically unstable and are therefore susceptible to recrystallization upon storage, particularly in hot and humid conditions^{4,9,10}.

All poorly water-soluble drugs are not suitable for improving their solubility by salt formation. The dissolution rate of a particular salt is usually different from that of parent compound. However sodium and potassium salts of weak acids dissolve more rapidly than the free salts. Potential disadvantages of salt forms include high reactivity with atmospheric carbon dioxide and water resulting in precipitation of poorly water-soluble drug, epigastric distress due to high alkalinity. Even though, use of co solvent to improve dissolution rate pose problems such as patient compliance and commercialization¹¹⁻¹².

Solid dispersion (SD) technique has been widely used to improve the dissolution rate, solubility and oral absorption of poorly water-soluble drugs¹³⁻¹⁴. The term solid dispersions have been utilized to describe a family of dosage forms whereby the drug is dispersed in a biologically inert matrix, usually with a view to enhancing oral bioavailability. Chiou and Riegelman defined these systems as the dispersion of one or more active ingredient in an inert carrier matrix at solid state prepared by the melting (fusion), solvent or melting-solvent method¹⁵.

Solubility enhancement strategies in Solid Dispersions: Various strategies investigated by several investigators include fusion (melting), solvent evaporation, lyophilization (freeze drying), melt agglomeration process, extruding method, spray drying technology, use of surfactant, electro static spinning method and super critical fluid technology.

- **Fusion method:** The fusion process is technically the less difficult method of preparing dispersions provided the drug and carrier are miscible in the molten state. This process employs melting of the

mixture of the drug and carrier in metallic vessel heated in an oil bath, immediately after fusion, the sample are poured onto a metallic plate which is kept at ice bath. A modification of the process involves spray congealing from a modified spray drier onto cold metal surface. Decomposition should be avoided and is affected by fusion time and rate of cooling¹⁶⁻¹⁷. Another modification of the above method, wherein SD(s) of troglitazone-polyvinyl pyrrolidone (PVP) K 30 have been prepared by closed melting point method. This method involves controlled mixing of water content to physical mixtures of troglitazone-PVP K30 by storing at various equilibrium relative humidity levels (adsorption method) or by adding water directly (charging method) and then mixer is heated. This method is reported to produce SD with 0% apparent crystallinity¹⁸.

On the other hand, the fusion process does not require an organic solvent but since the melting of sparingly water-soluble drug and water-soluble polymer entails a cooling step and solid pulverizing step, a time consuming multiple stage operation is required. To overcome this problem Nakano *et al.*,¹⁹ have described a method conceptualizing the formation of a SD as the solid-to-solid interaction between a sparingly water soluble drug, nilvadipine and water soluble polymer which, unlike conventional production method, comprises mixing a sparingly water soluble drug and water soluble polymer together under no more than the usual agitation force with heating within the temperature region not melting them, instead of heating the system to the extent that the two materials are melted, the sparingly water soluble drug can be made amorphous to have never been achieved by any dry process heretofore known.

- **Solvent Evaporation Method:** The solvent-based process uses organic solvent to dissolve and intimately disperse the drug and carrier molecule. Identification of a common solvent for both drug and carrier can be problematic, and complete solvent removal from the product can be a lengthy process. Moreover subtle alterations in the concentrations used for solvent evaporation may lead to large changes in the product performance. In addition large volumes of solvents are generally

required which can give rise to toxicological problems²⁰⁻²¹. Many investigators studied SD of meloxicam²², naproxen²³⁻²⁴, rofecoxib²⁵, felodipine²¹, atenolol²⁶, nimesulide²⁷ using solvent evaporation techniques. These findings suggest that the above-mentioned technique can be employed successfully for improvement and stability of solid dispersions of poorly water drugs.

Bhanbhun M Suhagic²⁸ suggested a method for preparation of SD of Etoricoxib employing solvent evaporation process wherein carriers poly ethyl glycol (PEG) and PVP along with drug were dissolved in propanol to get a clear solution and solvent was evaporated. The prepared SD(s) exhibited improved dissolution attributed to decreased crystallinity, improved wetting and improved bioavailability.

- **Lyophilization Technique:** Freeze-drying involves transfer of heat and mass to and from the product under preparation²⁹. This technique was proposed as an alternative technique to solvent evaporation. Lyophilization has been thought of a molecular mixing technique where the drug and carrier are co dissolved in a common solvent, frozen and sublimed to obtain a lyophilized molecular dispersion. G.V. Betageri *et al.*,³⁰ Yalcin Topalogh *et al.*,³¹ M. Badry *et al.*,³² and M. Fathy³³ have successfully investigated the potential applications of lyophilization in manufacturing of SD(s).

D J V Drooge *et al.*,³⁴ suggested spray freeze-drying as a potential alternative to the above-mentioned process to produce Δ^9 - tetrahydrocannabinol containing inulin-based solid dispersions with improved incorporation of Δ^9 - tetrahydrocannabinol in inulin.

- **Melt Agglomeration Process:** This technique has been used to prepare SD wherein the binder acts as a carrier. In addition, SD(s) are prepared either by heating binder, drug and excipient to a temperature above the melting point of the binder (melt- in procedure) or by spraying a dispersion of drug in molten binder on the heated excipient (spray-on procedure) by using a high shear mixer³⁵.

A rotary processor has been shown to be alternative equipment for melt agglomeration. The rotary processor might be preferable to the high melt agglomeration because it is easier to control the temperature and because a higher binder content can be incorporated in the agglomerates³⁶.

The effect of binder type, method of manufacturing and particle size are critical parameters in preparation of SD(s) by melt agglomeration. Since, these parameters result in variations in dissolution rates, mechanism of agglomerate formation and growth, agglomerate size, agglomerate size distribution and densification of agglomerates. It has been investigated that the melt-in procedure gives a higher dissolution rates than the spray-on procedure with PEG 3000, poloxamer 188 and gelucire 50/13 attributed to immersion mechanism of agglomerate formation and growth.

In addition the melt in procedure also results in homogenous distribution of drug in agglomerate. Larger particles results in densification of agglomerates while fine particles cause complete adhesion to the mass to the bowl shortly after melting attributed to distribution and coalescence of the fine particles³⁶⁻³⁸.

- **Extruding method:** The extruding method was originally designed as an extraction/casting method for polymer alloys in plastic industry, is now used to process cereals and functionalize food materials, such as tissue products from animal proteins³⁹. Hot melt extrusion approach represent the advantageous mean of preparation of SD(s) by using the twin screw hot melt extruder where only thermo stable components are relevant⁴⁰.

The extruder consists of a hopper, barrel, a die, a kneading screw and heaters. The physical mixture is introduced into the hopper that is forwarded by feed screw and finally is extruded from the die³⁹. The effect of screw revolution speed and water content on the preparation of SD(s) should be investigated, since these parameters have profound impact on the quality of SD(s).

Nakamichi *et al.*,⁴¹ studied that presence of kneading paddle element of screw results in super saturation on dissolution testing while slow revolution rate of screw and addition of the suitable amount of water increased rate of dissolution although no super saturation occurred. In addition, high screw speed-high feed rate processes in comparison with low screw speed-low feed rate processes caused an increase in extrudate radius and porosity and decrease in mechanical strength and drug release rate from the matrix attributed to the expansion promoted under certain extrusion conditions⁴².

To reduce the melt viscosity in the extrudate and to be able to decrease temperature settings, a plasticizer can be added to the formulation. Typically, conventional plasticizer such as triacetin or polyethylene glycol is used in concentration range of 5-30% weight of the extrudate that lowers the processing temperature. Carbon dioxide can act as temporary plasticizer. During extrusion carbon dioxide is transformed in gaseous phase. As a consequence carbon dioxide escapes from extrudate and does not appear in final product⁴³.

The role of methylparaben⁴⁴ and sorbitol⁴⁵ has also been investigated as plasticizer in preparation of SD(s) in extrusion method. This method has already been used successfully to prepare SD(s) of itraconazole and hydroxyl-propyl-methyl-cellulose (HPMC)⁴⁶, indomethacin/lacidipine/nefidipine/piroxicam/tolbutamide and polyvinylpyrrolidone (PVP)⁴⁷, itraconazole⁴⁸ and HPMC 2910/ Eudragit E 100 or a mixture of Eudragit E 100-PVP vinyl acetate⁶⁴ to improve solubility and dissolution rate of poorly water soluble drugs.

- **Spray Drying:** The manufacture of milk powder was one of the first applications of spray drying when the method was developed in 1920. Today, spray drying finds great utility in pharmaceutical industry because of the rapidly of drying and specific characteristics such as particle size and shape of the final product. In addition, it is simple and cost effective, as it is 30-50 times less expensive than freeze-drying. It is an established method that is initiated by atomizing suspensions or solutions into fine droplets followed by a drying

process, resulting solid particles. The process allows production of fine, dust free powder as well as agglomerated one to precise specifications. The operating conditions and dryer design depends upon the drying characteristics of the product and require powder specifications⁴⁹⁻⁵¹. SD(s) of loperamide and PEG 6000 were prepared by this technique, wherein solutions containing different concentrations of loperamide relative to the total amount of solid were spray dried. After spray drying, the dispersions were dried at 40°C under vacuum until constant weight. Solvent used was dichloromethane. The prepared SD(s) exhibited higher dissolution rates than that of pure crystalline Loperamide⁵².

Chouhan *et al.*,⁵³ studied the suitability of this technique for preparation of SD(s) of glibenclamide-polyglycolized glycerides. This study revealed the improvement in solubility and dissolution rates, also improvement in the therapeutics efficacy of amorphous glibenclamide in SD(s) was observed. Some other investigators⁵⁴⁻⁵⁵ also reported improvement in solubility and dissolution rate.

The frequent use of the organic solvent in spray drying pose problems such as residues in products, environmental pollution and operational safety as well as corporate problems such as capital investment. Tanno *et al.*,⁵⁶ described a process for producing the SD(s) of poorly water-soluble drugs using water-soluble polymer dispersion and/ or water-soluble polymer solution and the plasticizer solution by using 4-nozzle spray gun.

The spray drying technique is useful method to obtain spherical particle and narrow distribution. The role of porous materials such as calcium silicate, controlled pore glass and porous cellulose is appreciated to formulate solid dosages forms because they confer special characteristics such as decrease of melting point and a decrease in the crystallinity of drug entrapped in pores. In addition, porous materials control polymorphs and stabilizes meta-stable crystals in SD(s) under sever storage conditions. Moreover, porous silica has been reported to improve solubility and dissolution rates of indomethacin and tolbutamide⁵⁷⁻⁵⁸.

- **The use of Surfactant:** The utility of the surfactant systems in solubilization is well known. Adsorption of surfactant on solid surface can modify their hydrophobicity, surface charge, and other key properties that govern interfacial processes such as flocculation/dispersion, floatation, wetting, adsolubilization, detergency, enhanced oil recovery and corrosion inhibition. Surfactants have also been reported to cause solvation/plasticization, manifesting in reduction of melting of active pharmaceutical ingredients, glass transition temperature and the combined glass transition temperature of solid dispersions. Because of these unique properties, surfactants have attracted the attention of investigators for preparation of solid dispersions⁵⁹⁻⁶⁰.

Recently, a new class of surfactants, gelucires has been proposed with different melting points and HLB (hydrophilic and lipophilic balance) values. Gelucire excipients have been used in the formulation of semi solid dispersions. They are solid waxy materials, which are amphiphilic in character. Gelucires are the saturated polyglycolized glycerides consisting of mono-, di-, and tri-glycerides and of mono- and di- fatty acid esters of polyethylene glycol. The nature and proportion of each component are specific to a given grade of gelucire. Gelucires with low HLB can be employed to decrease the dissolution rate of drugs and higher HLB ones for fast release. Gelucire 44/14 and Gelucire 50/13 are two examples of this synthetic group where 44 and 50 represent melting point, while 14 and 313 represent HLB values of gelucire respectively⁶¹⁻⁶². Solid dispersions of antiviral agent UC-781-polyethylene glycol 6000-Gelucire 44/14 and UC-781- PEG 6000-gelucire 44/14- PVP K 30 were studied. Improvement in solubility, dissolution and stability was observed⁶³⁻⁶⁴.

Labrasol, of same chemical nature as gelucire, is a clear liquid surfactant with a HLB of 14. Solid dispersions of piroxicam with labrasol have also resulted in improved solubility and dissolution when compared with pure drug⁶¹⁻⁶². The amphiphilic poly (ethylene oxide)-poly (propylene oxide) - poly (ethylene oxide) (PEO-PPO-PEO) block polymers, known as Poloxamer or Pluronics

represent another class of surfactants. These are available in various molecular weights and PEO/PPO ratios, and hence offer a large variety of physico-chemical properties⁶⁵.

These block polymers are extensively used in the pharmaceutical industry as defoaming agents, gelling agents, detergents, dispersing agents, emulsifying agents and solubilizing agents⁶⁶. When used in relatively high quantities, poloxamer imparts sustained-release properties to solid dosage forms, by forming a lipid matrix⁶⁷.

Solid dispersions using pluronic F-68 (a type of poloxamer) as a carrier were studied for improving the dissolution and bioavailability of ABT-963, a poorly water soluble compound. Results showed that the solid dispersion substantially increased the in vitro-dissolution rate of ABT-963. A significant increase of oral bioavailability compared with conventional capsule formulation was also reported⁶⁸. The presence of water and polar water-miscible solvent, a partially water-miscible solvent, a non- ionic surfactant, an anionic surfactant and cationic surfactant affect domain of the PEO-PPO-PEO block copolymer self- assembly⁶⁹. Therefore, organic solvents and surfactants should be used with great care for preparation solid dispersion while using in combination with poloxamer.

Inutec SPI, a derivative of inulin prepared by the reaction between isocyanates and the polyfructose backbone in the presence of a basic catalyst such as a tertiary amine or lewis acid, has also been evaluated as carrier in formulation of solid dispersions for a poorly water soluble drug. Inutec SPI has low viscosity and stability effect on emulsion and suspension. Dissolution properties of SD(s) made up of itraconazole and Inutec SPI were improved in comparison to pure itraconazole or physical mixtures with Inutec SPI⁴. Hemant *et al.*,⁷⁰ and Sheen *et al.*,⁷¹ studied that polysorbate 80, a commonly used surfactant, results in improvement of dissolution and bioavailability of poorly water-soluble drug attributed to solubilization effect of surface active agent. Polysorbate 80 also ensures complete release of drug in metastable finely dispersed state having large surface area.

- **Electrospinning:** Electrospinning is a process in which solid fibers are produced from a polymeric fluid stream solution or melt delivered through a millimeter-scale nozzle⁷². This process involves the application of a strong electrostatic field over a conductive capillary attaching to a reservoir containing a polymer solution or melt and a conductive collection screen. Upon increasing the electrostatic field strength up to but not exceeding a critical value, charge species accumulated on the surface of a pendant drop destabilize the hemispherical shape into a conical shape (commonly known as Taylor's cone).

Beyond the critical value, a charged polymer jet is ejected from the apex of the cone (as a way of relieving the charge built-up on the surface of the pendant drop). The ejected charged jet is then carried to the collection screen via the electrostatic force. The coulombic repulsion force is responsible for the thinning of the charged jet during its trajectory to the collection screen. The thinning down of the charged jet is limited by the viscosity increase, as the charged jet is dried⁷³. This technique has tremendous potential for the preparation of nanofibers and controlling the release of biomedicine, as it is simplest, the cheapest⁷⁴⁻⁷⁷. This technique can be utilized for the preparation of solid dispersions in future.

- **Super Critical Fluid (SCF) Technology:** This technology has been introduced in the late 1980s and early 1990s, and experimental proofs of concept are abundant in the scientific literature for a plethora of model compounds from very different areas such as drugs and pharmaceutical compounds, polymers and biopolymers, explosives and energy materials, superconductors and catalyst precursors dyes and biomolecules such as proteins and peptides. From the very beginning of supercritical fluid particle generation research, the formation of biocompatible polymer and drug-loaded biopolymer micro-particles for pharmaceutical applications has been studied intensively by a number of researcher groups⁷⁸.

Since the first experiences of Hannay *et al.*, in 1879, a number of techniques have been developed and patented in the field of SCF-assisted

particle design. These methods use SCFs either as solvent: Rapid expansion from supercritical solution (RESS) or antisolvent: gas antisolvent (GAS), supercritical antisolvent (SAS), solution enhanced dispersion by supercritical fluids (SEDS) and/or dispersing fluid: GAS, SEDS, particles from gas-saturated solution (PGSS). Conventional methods i.e. spray drying; solvent evaporation and hot melt method often result in low yield, high residual solvent content or thermal degradation of the active substance⁷⁹.

In the supercritical fluid antisolvent techniques, carbon dioxide is used as an antisolvent for the solute but as a solvent with respect to the organic solvent. Different acronyms were used by various authors to denote micronization processes: aerosol solvent extraction system (ASES), precipitation with a compressed fluid anti-solvent (PCA), gas anti-solvent (GAS), solution enhanced dispersion by supercritical fluids (SEDS) and supercritical anti-solvent (SAS). The SAS process involves the spraying of the solution composed of the solute and of the organic solvent into a continuous supercritical phase flowing concurrently⁸⁰.

The use of supercritical carbon dioxide is advantageous as it is much easier to remove from the polymeric materials when the process is complete, even though a small amount of carbon dioxide remains trapped inside the polymer; it poses no danger to the patient. In addition the ability of carbon dioxide to plasticize and swell polymers can also be exploited and the process can be carried out near room temperature⁸¹. Moreover, supercritical fluids are used to lower the temperature of melt dispersion process by reducing the melting temperature of dispersed active agent. The reason for this depression is the solubility of the lighter component (dense gas) in the forming phase (heavier component)⁸².

Wong *et al.*, compared the SD(s) of felodipine prepared by conventional solvent evaporation (CSE) and supercritical antisolvent precipitation (SAS) methods. The particle sizes of the SD(s) from CSE process increased at 1h after dispersed in distilled water. However the particle sizes of the SD(s) from SAS process were maintained for 6 h

due to the increased solubility of felodipine. Moreover, SD(s) from the SAS process showed a high dissolution rate of over 90% within 2 h showing the potential applications of SCE technology in preparation of SD(s)⁸³.

CONCLUSION: The solubility of drugs in aqueous media is a key factor highly influencing their dissolution rate and bioavailability following oral administration resulting in low bioavailability. Solubility enhancement of these drugs remains one of the most challenging aspects of drug development. A variety of devices have been developed over the years to enhance the drug solubility and dissolution of the drugs. The solid dispersion method is one of the effective approaches to achieve the goal of solubility enhancement of poorly water-soluble drugs. Various techniques, described in this review, are successfully used for the preparation of SD(s) in the bench and lab scale and can be used at industrial scale also.

REFERENCES:

1. Ansel H C, Allen L V and Popovich CG. Eds. In; Pharmaceutical dosage forms and drug delivery systems, 7th Edn, Lippincott Williams and Wilkins, 2000, 60-61, 66.
2. Ohara T, Kitamura S, Kitagawa T and Terada K. Dissolution mechanism of poorly water-soluble drug from extended solid dispersion system with ethyl cellulose and hydroxypropyl methylcellulose. *Int. J. Pharm.* 302, 2005, 95-102.
3. Mooter G V den, Weuts I, Rider T D and Bleton N. Evaluation of Inutec SPI as a new carrier in the formulation of solid dispersion for poorly water drugs. *Int. J. Pharm.* 316, 2006, 1-6.
4. Hecq J, Deleers M, Fanara D, Vranckx H and Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. *Int. J. Pharm.* 299, 2005, 167-177.
5. Kapsi S G and Ayres J W. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. *Int. J. Pharm.* 299, 2001, 193-203.
6. Orienti I, Bigucci F, Luppi B, Cerchiara T, Zuccari G, Giunchedi P and Zecchi V. Polyvinylalcohol substituted with triethyleneglycolmonoethylether as a new material for preparation of solid dispersions of hydrophobic drugs. *Int. J. Pharm.* 54, 2002, 229-233.
7. Patro S, Himasankar K, Choudhury A A and Rao M E B. Effect of some hydrophilic polymers on dissolution rate of roxithromycin. *Indian J. Pharm. Sci.* 67(3), 2005, 334-341.
8. Omaira A S, Mohammed A H, Nagia A M and Ahmed S Z. Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersions. *AAPS PharmSciTech* 7(2), 2006, E1-E9.
9. Takano, Niichiro, Kawashima, Hiroyuki, Shinoda, Yasuo, Inagi and Toshio. Solid dispersion compositions. United States Patent No. 6753330, 2004.

10. Yiyun C, Tongwen X and Rongqiang F. Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. *Eur. J. Med. Chem.* 40, 2005, 1390-1393.
11. Mohan Babu G V M, Prasad D S, and Ramana Murthy K V. Evaluation of modified gum karaya as carrier for the dissolution enhancement of poorly water-soluble drug Nimodipine. *Int. J. Pharm.* 234, 2002, 1-17.
12. Gibaldi M. Ed., In; Biopharmaceutics and clinical pharmacokinetics, 4th Edn, Pharma Book Syndicate, Hyderabad, 2005, 48
13. Tanaka N, Imai K, Okimoto K, Ueda S, Rinta Ibuki Y T, Higaki K and Kimura T. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilcadipine(II): In vivo evaluation. *Journal of controlled release* 122, 2006, 51-56.
14. Duncan Q M C. The mechanism of drug release from solid dispersions in water-soluble polymers. *Int. J. Pharm.* 231, 2002, 131-144.
15. Hayes, Davis, Morella and Angelo Mario. Pharmaceutical compositions for poorly water-soluble drugs. United States Patent. No. 6881745, 2005.
16. Zerrouk N, Chemtob C, Arnaud P, Toscani S and Dugue J. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. *Int. J. Pharm.* 225, 2001, 49-62.
17. Boral A, Sen N, Ghosh L K and Gupta B K. Solid dispersion technology for controlling drug release and absorption. *The eastern pharmacist*, April 1995, 141-143.
18. Hasegawa S, Hamaura T, Furuyama N, Kusai A, Yonemochi E and Terada K. Effects of water contents in physical mixture and heating temperature on crystallinity of troglitazone- PVP K 30 solid dispersions prepared by closed melting method. *Int. J. Pharm.* 302, 2005, 103-112.
19. Nakano, Minoru, Uemura, Toshinobu, Morizane, Shinichi, Okuda, Kiyoshi, Nakata and Keiko. Method of producing a solid dispersion of a sparingly water-soluble drug, nilvadipine. United State Patent No. 5340591, 1994
20. Butler and Matthew J. Method of producing a solid dispersion of a poorly water-soluble drug. United State Patent No. 5985326, 1999.
21. Kim Eun-Jung, Chun M K, Jang J S, Lee I H, K R L and Choi H K. Preparation of a solid dispersion of felodipine using a solvent wetting method.
22. Chowdary K P R and R. Hymavathi. Enhancement of dissolution rate of meloxicam. *Indian J. Pharm. Sci.* April 2001, 150-154.
23. Rao M G, Suneetha R, Reddy P S and Ravi T K. Preparation and evaluation of solid dispersions of naproxen. *Indian J. Pharm. Sci.* 67(1), 2005, 26-29.
24. Mura P, Zerrouk N, Mennini N, Masterly F and Chemtob C. Development and characterization of naproxen solid systems with improved drug dissolution properties. *Eur. J. Pharm. Sci.* 18, 2003, 67-75.
25. Soniwala M M, Patel P R, Mansuri N S, Parikh R K and Gohel M C. *Indian J. Pharm. Sci.* 67(1), 2005, 61-65.
26. Moneghini M, Carcano A, Zingone G and Perissutti. Studies in dissolution enhancement of atenolol. *Int. J. Pharm.* 175, 1998, 177-183.
27. Jain R K, Sharma D K, Jain S, Kumar S and Dua J S. Studies on solid dispersions of nimesulide with pregelatinized starch. *Biosciences, biotechnology research Asia* 3(1a), 2006, 151-153.
28. Suhagia B N, Patel H M, Shah S A, Rathod I and Parmar V K. *Acta Pharm* 56, 2006, 285-298.
29. Tsinontides S C, Rajniak P, Pham D, Hunke W A, Placek, J and Reynolds S D. Freeze drying-principles and practice for

- successful scale-up to manufacturing. *Int. J. Pharm.* 280, No. 1, 2004, 1-16.
30. Betageri G V and Makarla K R. Enhancement of dissolution of Glyburide by solid dispersion and lyophilization techniques. *Int. J. Pharm.* 126, 1995, 155-160.
 31. Yalcin T, Gulgun Y and Gonullu U. Inclusion of ketoprofen with skimmed milk by freeze-drying. *Il Farmaco* 54, 1999, 648-652.
 32. Bandy M B and Fathy M. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30. *Drug Dev. Ind. Pharm.* 32 (2), 2006 Feb, 141-150.
 33. Fathy M and Sheha M. In vitro and in vivo evaluation of an amylobarbitone /hydroxypropyl-beta-cyclodextrin complex prepared by a freeze-drying method. *Pharmazie*. 55 (7), 2000 Jul, 513-517.
 34. Drooge D J V, Hinrichs W L J, Dickhoff H J, Elli M N A, Visser M R, Zijlstra G S and Frijlink H W. Spray freeze drying to produce a stable Δ^9 - tetrahydrocannabinol containing inulin based solid dispersion powder suitable for inhalation. *Eur. J. Pharm.* 26, 2005, 231-240.
 35. Seo A, Holm P, Kristensen H G, Schaefer T. The preparation of agglomerates containing solid dispersions of diazepam by melt agglomeration in a high shear mixer. *Int. J. Pharm.* 259(1-2), 2003 Jun 18, 161-71.
 36. Vilhelmsen T, Eliassen H, Schaefer T. Effect of a melt agglomeration process on agglomerates containing solid dispersions. *Int. J. Pharm.* 303(1-2), 2005 Oct 13, 132-142.
 37. Vilhelmsen T, Schaefer T. Agglomerate formation and growth mechanisms during melt agglomeration in a rotary processor. *Int. J. Pharm.* 304 (1-2), 2005 Nov 4, 152-164.
 38. Seo A and Schaefer T. Melt agglomeration with polyethylene glycol beads at a low impeller speed in a high shear mixer. *Eur. J. Pharm. Biopharm.* 52(3), 2001 Nov, 315-325.
 39. Wang L, Cui F D, Hayse T and Sunada H. Preparation and evaluation of solid dispersion for nitrendipine- carbopol and nitrendipine HPMCP systems using twin screw extruder. *Chem. Pharm. Bull.* 53(10), 2005, 1240-1245
 40. Zajc N, Obreza A, Bele M and Srcic S. Physical properties and dissolution behavior of nefidipine/mannitol solid dispersions prepared by hot melt method. *Int. J. Pharm.* 291, 2005, 51-58.
 41. Nakamichi K, Nakano T, Yasuura H, Izumi S and Kawashima Y. The role of the kneading paddle and the effects of screw revolution speed and water content on the preparation of solid dispersions using a twin-screw extruder. *Int. J. Pharm.* 241(2), 2002 Jul 25, 203-211.
 42. Six K, Verreck G, Peeters J, Brewster M and Van Den Mooter G. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. *J. Pharm. Sci.* 93(1), 2004 Jan, 124-131.
 43. Verreck G, Decorte A, Heymans K, Adriaensen J, Liu D, Tomasko D, Arien A, Peeters J, Mooter G V den and Brewster M E. Hot stage extrusion of *p*-amino salicylic acid with EC using CO₂ as a temporary plasticizer. *Int. J. Pharm.* 327, 2006, 45-50.
 44. Wu C and McGinity J W. Influence of methylparaben as a solid-state plasticizer on the physicochemical properties of Eudragit RS PO hot-melt extrudates. *Eur. J. Pharm. Biopharm.* 56(1), 2003 Jul, 95-100.
 45. Henrist D, Lefebvre R A and Remon J P. Bioavailability of starch based hot stage extrusion formulations. *Int. J. Pharm.* 187(2), 1999 Oct 5, 185-91.
 46. Six K, Berghmans H, Leuner C, Dressman J, Van Werde K, Mullens J, Benoist L, Thimon M, Meublât L, Verreck G, Peeters J, Brewster M and Van den Mooter G. Characterization of solid dispersions of itraconazole and hydroxypropyl- methylcellulose prepared by melt extrusion, Part II. *Pharm. Res.* 20(7), 2003 Jul, 1047-1054.
 47. Forster A, Hemenstall J, Tucker and Rades T. The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer blends for melt extrusion. *Drug Dev. Ind. Pharm.* 27(6), 2001 Jul, 549-560.
 48. Six K, Daems T, de Hoon J, Van Hecken A, Depre M, Bouche MP, Prinsen P, Verreck G, Peeters J, Brewster ME and Van den Mooter G. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. *Eur. J. Pharm. Sci.* 24(2-3), 2005 Feb, 179-186.
 49. Chronakisa I S, Triantafyllou A O, R O^{ste}. Solid-state characteristics and redispersible properties of powders formed by spray-drying and freeze-drying cereal dispersions of varying (1 3, 1 4) - β -glucan content. *Journal of cereal science* 40, 2005, 183-193.
 50. Patrice T T, Stephanie B and Hatem F. Preparation of redispersible dry nanocapsules by means of spray drying: Development and characterization. *Eur. J. Pharm. Sci.* 30, 2007, 124-135.
 51. Rankell A S, Lieberman H A and Schiffmann R F. Drying. In: L. Lachman, H.A. Lieberman and J.L. Kanig eds. *The theory and practice of industrial pharmacy*. 3rd edition, Varghese Publishing house, Bombay, 1987, pp no 61.
 52. Weuts I, Kempen D, Verreck G, Decorte A, Heymans K, Peeters J, Brewster M and Mooter G V den. Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG 6000 prepared by spray drying. *Eur. J. Pharm. Biopharm.* 59, 2005, 119-126.
 53. Chauhan B, Shimpi S and Paradkar A. Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. *Eur. J. Pharm. Sci.* 26, 2005, 219-230.
 54. Ueno Y, Yonemochi E, Tozuka Y, Yamamura S, Oguchi T and Yamamoto K. Characterization of amorphous ursodeoxycholic acid prepared by spray-drying. *J. Pharm. Pharmacol.* 50(11), 1998 Nov, 1213-1219
 55. Chen R, Tagawa M, Hoshi N, Ogura T, Okamoto H and Danjo K. Improved dissolution of an insoluble drug using a 4-fluid nozzle spray-drying technique. *Chem. Pharm. Bull.* 52(9), 2004 Sep, 1066-1070.
 56. Tanno, Fumie, Nishiyama and Yuichi. Process for producing a pharmaceutical solid preparation containing a poorly soluble drug. United States patent No. 6872336.
 57. Takeuchi H, Nagira S, Yamamoto H and Kawashima Y. Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. *Int. J. Pharm.* 293, 2005, 155-164.
 58. Takeuchi H, Nagira S, Yamamoto H and Kawashima Y. Solid dispersion particles of tolbutamide prepared with fine silica particles by the spray-drying method. *Powder technology* 141, 2004, 187-195.
 59. Ghebremeskel A N, Vemavarapu C and Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: Selection of polymer-surfactant combinations using solubility parameters and testing the processability. *Int. J. Pharm.* 328, 2007, 119-129.
 60. Zhang R and Somasundaran P. Advances in adsorption of surfactants and their mixtures at solid/solution interfaces. *Advances in colloid and interface science* 123-126, 2006, 213-229.

61. Karatas A, Yüksel N and T Baykara. Improved solubility and dissolution rate of piroxicam using Gelucire 44/14 and Labrasol. *Il Farmaco* 60, 2005, 777-782.
62. Yüksek N, Karatas A, Yalcın O, Zkan, Ayhan Savas, er, Sibel A. Özkan and Baykara T. Enhanced bioavailability of piroxicam using Gelucire 44/14 and Labrasol: in vitro and in vivo evaluation. *Eur. J. Pharm. Biopharm.* 56, 2003, 453-459.
63. Damian F, Blaton N, Naesens L, Balzarini J, Kinget R, Augustijns P and Mooter G Van den. Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. *Eur. J. Pharm. Sci.* 10, 2000, 311-322.
64. Damian F, Blaton N, Kinget R and Mooter G Van den. Physical stability of solid dispersions of the antiviral agent UC-781 with PEG 6000, Gelucire† 44/14 and PVP K3. *Int. J. Pharm.* 244, 2002, 87-98.
65. Ivanova R, Lindman B and Alexandridis P. Effect of pharmaceutically acceptable glycols on the stability of the liquid crystalline gels formed by poloxamer 407 in water. *J of Colloid and Interface Sci.* 252, 2002, 226-235.
66. Erlandsson B. Stability-indicating changes in poloxamers: the degradation of ethylene oxide-propylene oxide block copolymers at 25 and 40°C. *Polymer degradation and stability* 78, 2002, 571-575.
67. Jannin V, Pochard E and Chambin O. Influence of poloxamers on the dissolution performance and stability of controlled-release formulations containing Precirol® ATO 5. *Int. J. Pharm.* 309, 2006, 6-15.
68. Chen Y, Zhang G G Z, Neilly J, Marsh K, Mawhinney D and Sanzgiri Y D. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-6. *Int. J. Pharm.* 286, 2004, 69-80.
69. Ivanova R, Alexandridis P and Lindman B. Interaction of poloxamer block copolymers with co solvents and surfactants. *Colloids and Surfaces A: Physicochemical and Engineering Aspects* 183-185, 2001, 41-53.
70. Joshi H N, Tejwani R W, Davidovich M, Sahasrabudhe V P, Jemal M, Bathala M S, Varia S A and Serajuddin A T M. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. *Int. J. Pharm.* 269, 2004, 251-258.
71. Sheen P C, Khetarpal V K, Cariola C.M and Rowlings C E. Formulation studies of a poorly water-soluble drug in solid dispersions to improve bioavailability. *Int. J. Pharm.* 118, 1995, 221-227.
72. Hohman M M, Shin M, Rutledge G and Michael P. Brennera electrospinning and electrically forced jets. II. Applications. *Physics of fluids*, 13(8), 2001, 2221-2236.
73. Neamark A, Rujiravanit R and Supaphol P. Electrospinning of hexanoyl Chitosan. *Carbohydrate polymers* 66, 2006, 298-305.
74. Zhang W, Yan E, Huang Z, Wang C, Xin Y, Zhao Q, and Tong Y. Preparation and study of PPV/PVA nanofibers via electrospinning PPV precursor alcohol solution. *European polymer* 43, 2007, 802-897.
75. Kenawy E R, Abdel-Hay F I, El-Newehya M H and Wnekb G E. Controlled release of ketoprofen from electrospun poly (vinyl alcohol) nanofibers. *Materials Science and Engineering A* 459, 2007, 390-396.
76. Bai J, Yaoxian L, Songtao Y, Jianshi D, Shugang W, Jifu Z, Yongzhi W, Qingbiao Y and Xuesi C X J. A simple and effective route for the preparation of poly (vinylalcohol) (PVA) nanofibers containing gold nanoparticles by electrospinning method. *Solid State Communications* 141, 2007, 292-295.
77. Jiranun M, Manit N and Pitt S. Effects of solvent properties, solvent system, electrostatic field strength, and inorganic salt addition on electrospun polystyrene fibres. *Iranian Polymer Journal*, 15 (4), 2006, 341-354.
78. Muhrer G, Meier U, Fusaro F, Albano S and Mazzotti M. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water-soluble drug: generation of drug microparticles and drug-polymer solid dispersions. *Int. J. Pharm.* 308, 2006, 69-83.
79. Majerik V, Charbit G, Badens E, Horv'ath G, Szokonya L, Bosc N and Teillaud E. Bioavailability enhancement of an active substance by supercritical antisolvent precipitation. *J of Supercritical Fluids* 40, 2007, 101-110.
80. Taki S, Badens E and Charbit G. Controlled release system formed by supercritical anti-solvent coprecipitation of a herbicide and a biodegradable polymer. *J of Supercritical Fluids* 21, 2001, 61-70.
81. Manna L, Banchemo M, Solta D, Ferri A, Ronchetii S and Sicrdi S. Impregnation of PVP microparticles with ketoprofen in the presence of supercritical CO₂. *J of Supercritical Fluids* 2006 article in press.
82. Dohrn R, Bertakis E, Behrend O, Voutsas E and Tassios D. Melting point depression by using supercritical CO₂ for a novel melt dispersion micronization process. *J of Molecular Liquids* 131-132, 2007, 53-59.
83. Wong D H, Kim M S, Lee S, Jeong S P and Hwang S J. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. *Int. J. Pharm.* 301, 2005, 199-208.
